John A. Blessing

17.7k total citations · 2 hit papers
261 papers, 13.1k citations indexed

About

John A. Blessing is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, John A. Blessing has authored 261 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Reproductive Medicine, 129 papers in Obstetrics and Gynecology and 88 papers in Surgery. Recurrent topics in John A. Blessing's work include Ovarian cancer diagnosis and treatment (151 papers), Endometrial and Cervical Cancer Treatments (105 papers) and Uterine Myomas and Treatments (48 papers). John A. Blessing is often cited by papers focused on Ovarian cancer diagnosis and treatment (151 papers), Endometrial and Cervical Cancer Treatments (105 papers) and Uterine Myomas and Treatments (48 papers). John A. Blessing collaborates with scholars based in United States, Canada and Italy. John A. Blessing's co-authors include William T. Creasman, Philip J. DiSaia, Howard D. Homesley, Peter G. Rose, J.T. Thigpen, Gregory P. Sutton, Francis J. Major, Hugh M. Shingleton, Leo D. Lagasse and Edgardo Yordan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

John A. Blessing

257 papers receiving 12.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

2004 479 citations John A. Blessing, David S. Miller et al. Journal of Clinical Oncology profile →
Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study

1993 464 citations Francis J. Major, John A. Blessing et al. profile →

Peers

Countries citing papers authored by John A. Blessing

Since Specialization

Citations

This map shows the geographic impact of John A. Blessing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Blessing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Blessing more than expected).

Fields of papers citing papers by John A. Blessing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Blessing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Blessing. The network helps show where John A. Blessing may publish in the future.

Co-authorship network of co-authors of John A. Blessing

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Blessing. A scholar is included among the top collaborators of John A. Blessing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Blessing. John A. Blessing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial 2008 ·Gynecologic Oncology ·Martee L. Hensley, John A. Blessing, Robert S. Mannel, Peter G. Rose	226
2	Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix 2007 ·American Journal of Clinical Oncology ·Agustin A. García, John A. Blessing, Luis Vaccarello, Lynda D. Roman	48
3	Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study 2003 ·Gynecologic Oncology ·(unknown), John A. Blessing, Roger B. Lee, Thomas F. Rocereto	134
4	A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study 2003 ·Investigational New Drugs ·Deborah K. Armstrong, John A. Blessing, Janet S. Rader, Joel I. Sorosky	16
5	Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study 2002 ·Gynecologic Oncology ·Steven C. Plaxe, John A. Blessing, Michael A. Bookman, William T. Creasman	11
6	A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study 2002 ·Gynecologic Oncology ·David S. Miller, John A. Blessing, Samuel S. Lentz, Steven Waggoner	76
7	Evaluation of Recombinant Human Interleukin-12 in Patients with Recurrent or Refractory Ovarian Cancer: A Gynecologic Oncology Group Study 2001 ·Gynecologic Oncology ·Jean Hurteau, John A. Blessing, Steven DeCesare, William T. Creasman	73
8	Phase II Trial of Paclitaxel in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study 1999 ·Gynecologic Oncology ·Gregory P. Sutton, John A. Blessing, Harrison Ball	57
9	Intraperitoneal α-Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study 1999 ·Gynecologic Oncology ·J. S. Berek, Maurie Markman, John A. Blessing, Paul R. Kucera, Beth E. Nelson, Barrie Anderson, Parviz Hanjani	25
10	A Phase II Trial of Isotretinoin and Alpha Interferon in Patients With Recurrent Squamous Cell Carcinoma of the Cervix 1998 ·American Journal of Clinical Oncology ·Katherine Y. Look, John A. Blessing, Beth E. Nelson, Gary A. Johnson, Wesley C. Fowler, Gary C. Reid	18
11	Amonafide in Patients With Leiomyosarcoma of the Uterus 1998 ·American Journal of Clinical Oncology ·Robert F. Asbury, John A. Blessing, Richard E. Buller, John H. Malfetano, Joan L. Walker, Bernd‐Uwe Sevin	15
12	A Phase II Study of Intraperitoneal Cisplatin and Thiotepa in Residual Ovarian Carcinoma: A Gynecologic Oncology Group Study 1998 ·Gynecologic Oncology ·Lynn G. Feun, John A. Blessing, Francis J. Major, Philip J. DiSaia, Ronald D. Alvarez, Jonathan S. Berek	15
13	Phase II Evaluation of Altretamine for Advanced or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study 1996 ·Gynecologic Oncology ·Peter G. Rose, John A. Blessing, James C. Arseneau	13
14	Echinomycin (NSC 526417) in Recurrent and Metastatic Nonsquamous Cell Carcinoma of the Cervix 1992 ·American Journal of Clinical Oncology ·Hyman B. Muss, John A. Blessing, Parviz Hanjani, John H. Malfetano, (unknown), Kenneth Webster	6
15	Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon 1992 ·Gynecologic Oncology ·Maurie Markman, Jonathan S. Berek, John A. Blessing, William P. McGuire, Jeffrey G. Bell, Howard D. Homesley	39
16	Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. 1991 ·Journal of Clinical Oncology ·J.T. Thigpen, John A. Blessing, Jackson B. Beecham, Howard D. Homesley, Edgardo Yordan	119
17	Methotrexate in Advanced Endometrial Carcinoma 1990 ·American Journal of Clinical Oncology ·Hyman B. Muss, John A. Blessing, Kenneth D. Hatch, John T. Soper, Kenneth Webster, (unknown)	9
18	Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix 1989 ·Investigational New Drugs ·Gregory P. Sutton, John A. Blessing, Leon L. Adcock, Kenneth Webster, (unknown)	44
19	A Phase II study of CHIP in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study) 1986 ·Investigational New Drugs ·William P. McGuire, John A. Blessing, Kenneth D. Hatch, Philip J. DiSaia	13
20	A Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study) 1986 ·Investigational New Drugs ·James C. Arseneau, John A. Blessing, Frederick B. Stehman, Ramon McGehee	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact